Aimei Health Technology Co., Ltd. filed a Current Report on Form 8-K dated November 10, 2026, detailing the results of an Extraordinary General Meeting held virtually on that same date. The meeting addressed four key proposals regarding the company's governance and trust agreement.
The primary outcome was the approval of an amendment to the company's Articles of Association. Shareholders voted to extend the deadline for the company to consummate a business combination from 36 months following its initial public offering (IPO) to 48 months. The IPO occurred on December 6, 2026; consequently, the new deadline is set for December 6, 2027. This change was approved as a special resolution with 2,757,268 votes in favor.
Separately, the company entered into a third amendment to its Investment Management Trust Agreement with Continental Stock Transfer & Trust Company as trustee. This amendment reflects the extension of the business combination deadline. The filing specifies that the amount of funds required to be deposited into the trust account for each monthly extension remains the lesser of $80,000 for all outstanding ordinary shares sold in the IPO or $0.033 for each outstanding Public Share.
Shareholders also approved the appointment of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the meeting approved a proposal allowing the chairman to adjourn the meeting to a later date if necessary to secure votes for the proposals.
In other events, the report notes that as of the reporting date, holders of 841,629 Public Shares exercised their right to redeem those shares for cash at an approximate price of $12.33 per share. This resulted in an aggregate redemption amount of approximately $10,377,384. Following these redemptions, the Trust Account balance is approximately $2,450,031, and the company has 2,324,703 ordinary shares outstanding.